tbuckley/cabot-search huggingface dataset:
A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2
Authors: D. P. Steensma, R. Molina, J. A. Sloan, D. A. Nikcevich, P. L. Schaefer, K. M. Rowland, T. Dentchev, L. K. Tschetter, P. J. Novotny, C. L. Loprinzi
Journal: Journal of Clinical Oncology (2005)

8031 Background: Weekly EPO therapy is beneficial for anemic cancer patients (pts), but it would be more convenient for pts if EPO could be administered less frequently. Methods: 365 pts with cancer-associated anemia (Hb <12 g/dL for males or <11 g/dL for females) at 16 NCCTG sites received 3 doses of weekly 40,000U EPO subcutaneously (SC) and were randomized (5 stratification variables) to continue standard weekly EPO (40K arm, n=183) or to receive 120,000U EPO SC every 3 weeks (120K arm, n=182) for 18 additional weeks. All pts received FeSO4 325mg orally once daily. Eligible pts had ECOG PS 0–2, were not iron deficient, and did not need to be receiving active anti-neoplastic therapy (but 89% were). The primary endpoint was the proportion of pts requiring transfusion in each group; secondary endpoints included hemoglobin (Hb) levels, quality of life (QOL), toxicity, and survival. There was 80% power to detect a 9% difference in the primary endpoint of transfusion rate between treatment groups. Results: There was no difference in the overall transfusion rate (19% in 40K arm, 16% in 120K arm, p=0.51). Pts on 40K were more likely to have a ≥2 or ≥3 g/dL Hb increment from baseline (70% vs. 60% for 2 g/dL, p=0.04), more likely to have an EPO dose held due to high Hb (56% vs. 34%, p=0.0001 - but Hb measurements occurred more frequently in the 40K arm), and had a higher final Hb (11.9 vs. 11.4, p=0.002) and higher likelihood of exceeding Hb >13 at some point (58% vs. 38%, p=0.0001). Leukopenia was reported more often in the 40K arm (17% vs. 10%, p=0.03) but infection rate was not higher. Other toxicities were equivalent. There was a slight trend towards superior survival in the 120K arm (p=0.10). Pts on 40K had a higher overall UNISCALE QOL at baseline (mean 67 vs. 62, p=0.03), while pts in the 120K arm had a greater improvement in QOL during the study (mean change -0.7 vs. +5.4, p=0.02), so the end-of-study QOL was equivalent between arms. There were no differences in other QOL scores (e.g., FACT-An and Brief Fatigue Inventory). Conclusions: After 3 weekly doses, EPO can be administered at a higher dose every 3 weeks without increasing transfusion needs or sacrificing QOL. No significant financial relationships to disclose.
Carcinogenicity of Fibrous Glass: Pleural Response in the Rat in Relation to Fiber Dimension
Authors: Mearl F. Stanton, Maxwell Layard, Andrew Tegeris, Eliza Miller, Margaret May, Elizabeth Kent
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Carcinogenicity of Fibrous Glass: Pleural Response in the Rat in Relation to Fiber Dimension Get access Mearl F. Stanton, Mearl F. Stanton Search for other works by this author on: Oxford Academic PubMed Google Scholar Maxwell Layard, Maxwell Layard Search for other works by this author on: Oxford Academic PubMed Google Scholar Andrew Tegeris, Andrew Tegeris Search for other works by this author on: Oxford Academic PubMed Google Scholar Eliza Miller, Eliza Miller Search for other works by this author on: Oxford Academic PubMed Google Scholar Margaret May, Margaret May Search for other works by this author on: Oxford Academic PubMed Google Scholar Elizabeth Kent Elizabeth Kent Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 3, March 1977, Pages 587–603, https://doi.org/10.1093/jnci/58.3.587 Published: 01 March 1977 Article history Received: 06 July 1976 Accepted: 15 September 1976 Published: 01 March 1977
Matrix stiffness modulates formation and activity of neuronal networks of controlled architectures
Authors: Joséphine Lantoine, Thomas Grevesse, Agnès Villers, Geoffrey Delhaye, Camille Mestdagh, Marie Versaevel, Danahe Mohammed, Céline Bruyère, Laura Alaimo, Stéphanie P. Lacour, Laurence Ris, Sylvain Gabriele
Journal: Biomaterials (2016)
Efficacy and safety of oral vinorelbine (NVBO) in first- or second-line metastatic breast cancer (MBC).
Authors: I. Blancas, S. Morales, N. Diaz, A. Barnadas, M. L. Gonzalvez, S. del Barco, M. H. Lopez de Ceballos, F. J. Perez, A. Llombart-Cussac
Journal: Journal of Clinical Oncology (2010)

1090 Background: NVBO has shown high activity and good safety profile when given as single agent chemotherapy (CT) for MBC. Oral CT formulations allow maintenance of quality of life and minimal interference with a normal lifestyle. Methods: Main inclusion criteria for this observational analysis were: histologically or citologically confirmed MBC, no more than 1 prior CT line for MBC; prior (neo)adjuvant CT, hormonetherapy or radiotherapy allowed; adequate bone marrow, kidney, and liver function. All patients were treated with NVBO 60 mg/m2 weekly until progression or unacceptable toxicity. Between April 2006 and October 2009, 45 patients fulfilled the inclusion criteria. Patient's characteristics were: median age, 63 years (range 38-82); >75 years old, 16%; ECOG PS 0-1 in 41 p (91%) and PS 2 in 4 p (9%); ER+ and/or PR+, 24 p (53%); >2 metastatic sites in 64%; prior (neo)adjuvant CT in 41 p (91%); prior hormonotherapy, 30 p (67%). Measurable disease in 40 p (89%). 1 p received trastuzumab concomitantly. Results: Median number of administrations (a) 9 (range 2-36). We analyzed 553 a. Delayed due to hematological toxicity in 3.7% weeks (w), related nonhematological toxicity in 1.6% w. dose was reduced in 2% w. hematological toxicities (%w): neutropenia grade (g) 3, 0.9%; no febrile neutropenia was observed. Nonhematological toxicities (%w): pain g 3-4, 0.6%; constipation g 3, 0.2%, ileus paraliticus g 3, 0.2%; infection g 3, 0.2%. 44 p were evaluable for response. 13 PR (29.5%) and 13 SD (29.5%) were reported. Objective response (OR) rate 29.5%. Median time to progression 4 m [CI 95%, 1.4-6.5]. Median progression-free survival 4 m [CI 95%, 1.4-6.5]. 4 patients had died at the time of cut-off date. Conclusions: Our findings confirm the consistently produced clinically meaningful efficacy of single agent NVBO for MBC. We observed a favorable safety profile with a particular low incidence of myelosupression and alopecia. We consider that oral vinorelbine is a suitable first or second-line treatment for convenient administration in an outpatient environment in selected p with MBC. No significant financial relationships to disclose.
Accelerated Brain Aging in Schizophrenia: A Longitudinal Pattern Recognition Study
Authors: Hugo G. Schnack, Neeltje E.M. van Haren, Mireille Nieuwenhuis, Hilleke E. Hulshoff Pol, Wiepke Cahn, René S. Kahn
Journal: American Journal of Psychiatry (2016)

Objective: Despite the multitude of longitudinal neuroimaging studies that have been published, a basic question on the progressive brain loss in schizophrenia remains unaddressed: Does it reflect accelerated aging of the brain, or is it caused by a fundamentally different process? The authors used support vector regression, a supervised machine learning technique, to address this question. Method: In a longitudinal sample of 341 schizophrenia patients and 386 healthy subjects with one or more structural MRI scans (1,197 in total), machine learning algorithms were used to build models to predict the age of the brain and the presence of schizophrenia (“schizophrenia score”), based on the gray matter density maps. Age at baseline ranged from 16 to 67 years, and follow-up scans were acquired between 1 and 13 years after the baseline scan. Differences between brain age and chronological age (“brain age gap”) and between schizophrenia score and healthy reference score (“schizophrenia gap”) were calculated. Accelerated brain aging was calculated from changes in brain age gap between two consecutive measurements. The age prediction model was validated in an independent sample. Results: In schizophrenia patients, brain age was significantly greater than chronological age at baseline (+3.36 years) and progressively increased during follow-up (+1.24 years in addition to the baseline gap). The acceleration of brain aging was not constant: it decreased from 2.5 years/year just after illness onset to about the normal rate (1 year/year) approximately 5 years after illness onset. The schizophrenia gap also increased during follow-up, but more pronounced variability in brain abnormalities at follow-up rendered this increase nonsignificant. Conclusions: The progressive brain loss in schizophrenia appears to reflect two different processes: one relatively homogeneous, reflecting accelerated aging of the brain and related to various measures of outcome, and a more variable one, possibly reflecting individual variation and medication use. Differentiating between these two processes may not only elucidate the various factors influencing brain loss in schizophrenia, but also assist in individualizing treatment.
Weekly docetaxel as second-line (palliative) chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma (SCCHN)
Authors: H. Koussis, A. Scola, F. Bergamo, S. Tonello, A. Jirillo, U. Basso, L. M. Pasetto, P. Sperandio, M. E. Donach, S. Monfardini
Journal: Journal of Clinical Oncology (2007)

6067 Background: Relapse or distant metastases of squamous cell carcinoma of the head and neck (SCCHN) is considered to have poor prognosis with survival time of less than one year. Presently, there s no standard treatment even if palliative chemotherapy is widely used. In this setting in recent years taxanes are among the most widely used agents. Methods: From December 2004 to October 2006 24 pts (20 male and 4 female, 12 over 60 yrs) with recurrent metastatic squamous cell carcinoma were consecutively accrued and treated with weekly docetaxel 35mg/m2 for 3 of 4 weeks. Median age was 59 (range 34–74). All had good performance status (ECOG 0- 1) and had received previous standard platinum-based regimen. Primary endpoints were response rate, duration of response, time to progression and toxicity evaluation. Results: A total of 83 courses of weekly docetaxel were administered (mean 3.5; range 1–10 courses). Six partial responses (25%) (RECIST criteria) with mean duration of 3.4 months, 6 stable and 12 progressive disease were observed; no complete responses were obtained. Time to progression was 3.2 months (range 1.2–9 months). Of note, response rates and toxicity were similar in patients above (12 pts) and below (12 pts) 60 yrs. Toxicity was mild: G4 mucositis in 3 pts and G3-G4 hematologic in 4 pts. Conclusions: These data suggest that a weekly schedule of docetaxel is active and tolerable as second line therapy in patients with metastatic/recurrent SCCHN. The response rate is slightly better than that described in the literature which averages 15–20%. The schedule is easy to administer to out patients and also seems possible for elderly patients. No significant financial relationships to disclose.
Comment on Shukla et al. Food Order Has a Significant Impact on Postprandial Glucose and Insulin Levels. Diabetes Care 2015;38:e98–e99
Authors: Saeko Imai, Michiaki Fukui, Shizuo Kajiyama
Journal: Diabetes Care (2015)

We appreciated the article by Shukla et al. (1) showing that food order had a significant impact on postprandial glucose and insulin levels in obese patients with type 2 diabetes in U.S. However, we have already reported not only the same effect of eating vegetables before carbohydrates on postprandial glucose and insulin levels but also a significant improvement of HbA1c by as much as 1.5% in outpatients with type 2 diabetes who received instructions …
Prognostic Impact of Tumoral and/or Peri-Tumoral Sparc Expressions After Surgery in Patients with Biliary Tract Cancer
Authors: D. Sakai, S. Nakashima, S. Kobayashi, M. Konno, N. Nishida, T. Kudo, A. Tomokuni, Y. Tomimaru, N. Hama, H. Wada, K. Kawamoto, S. Marubashi, H. Eguchi, N. Matsuura, T. Satoh, H. Nagano, Y. Doki, M. Mori
Journal: Annals of Oncology (2014)
Outcomes of an organized breast cancer screening program over the past 15 years.
Authors: Rasika Rajapakshe, Brent Parker, Cynthia Araujo, Christina Chu, Christine Wilson, Janette Sam
Journal: Journal of Clinical Oncology (2012)

14 Background: Founded in 1988, The Screening Mammography Program of British Columbia (SMPBC) is a large, and stable screening program and a formal review of its effectiveness provides suggestions for further improvements. The purpose of this study is to quantify and report trends of the SMPBC and to assess if there have been any major changes in outcomes over the past fifteen years as this program has matured. Methods: A retrospective review of the SMPBC was performed by extracting data from the past 15 years from the SMPBC Annual Reports. The changes and trends in percentage of eligible population screened/participation rate, number of screening exams and number of first screens performed, overall cancer detection rate, and DCIS detection rate was extracted and reported. Furthermore, cost analysis data was extracted, and adjusted to compensate for inflation using The Bank of Canada Inflation Calculator, which bases its calculations from the Canadian Consumer Price Index (CPI) from Statistics Canada. Results: Over the past 15 years, the total number of exams provided per year has almost doubled from 166,746 in 1996 to 303,157 in 2010, and this increase accommodates the overall and aging growth of the BC population. An increasing participation rate is seen from 1999-2009 for women from rural sites and traditionally underserved areas of British Columbia, while the overall participation rate over this time period remains stable (range 48%-51%). The cancer detection rate also remains stable (range: 3.4-4.5 cases per 1000 screens). After adjusting for inflation, a 12.6% increase in the cost per screen from 1995-2009 is observed. This increase is multifactorial and includes an increase in operating costs central services and physician reading fees. Conclusions: The province of British Columbia has consistently had the lowest rates of breast cancer related mortality in Canada, and this may be, in part, because of the long term stability of the BC Screening Mammography Program. Our report suggests that the SMPBC has been effective in accommodating the growing aging population, although there is still room for improvement, as a target participation of 70% is considered the standard to effectively reduce mortality through screening.
Final results of a study comparing short-course and long-course radiotherapy (RT) for local control of metastatic spinal cord compression (MSCC)
Authors: D. Rades, M. Lange, T. Veninga, L. J. Stalpers, A. Bajrovic, I. A. Adamietz, V. Rudat, S. E. Schild
Journal: Journal of Clinical Oncology (2009)

9522 Background: Many MSCC patients live long enough to develop a recurrence in the irradiated spinal area. This is the first prospective study comparing different RT schedules for local control (LC) of MSCC. Methods: 265 patients treated with RT alone (1/06–12/07) were included in this prospective non-randomized study. The primary goal was to compare short-course (1×8 Gy/5×4 Gy, N=131) and long-course RT (10×3 Gy/15×2.5 Gy/20×2 Gy, N=134) for 1-year LC. Secondary endpoints were motor function and 1-year survival (OS). Dutch patients received short-course, and German patients long-course RT. The analysis of LC (no MSCC recurrence in the irradiated spinal area) included the 224 patients with improvement or no change of motor deficits during RT. The difference in 1-year LC was previously reported to be 14% between short- and long-course RT. For a statistical power of 90 % (significance level 5%), ≥218 patients were required to detect this difference. Univariate analyses (UVA) for LC and OS were performed with Kaplan-Meier-method and log-rank test, multivariate analyses (MVA) with the Cox proportional hazards model. UVA and MVA for motor function were performed with the ordered-logit-model. Eleven additional factors were evaluated. Results: 1-year LC was 61% after short-course RT and 81% after long-course RT (P=0.005). On MVA, improved LC was only associated with long-course RT (P=0.018). Motor function improved in 37% after short- and 39% after long-course RT (P=0.95). Improved motor function was associated with better performance status (P=0.015), favorable tumor (P=0.034), and slower development of motor deficits (P&lt;0.001). 1-year OS was 23% after short- and 30% after long-course RT (P=0.28). On MVA, improved OS was associated with better performance status (P&lt;0.001), no visceral metastases (P&lt;0.001), involvement of 1–3 vertebrae (P=0.040), ambulatory status (P=0.038), and bisphosphonates (P&lt;0.001). Conclusions: Long-course RT was associated with better LC, similar functional outcome, and similar OS compared to short-course RT. Patients with a favorable OS prognosis should receive long-course RT, and those with a poor OS prognosis should receive short-course RT. [Table: see text]
Avoiding late-stage colorectal cancer: The outpatient safety net.
Authors: Joanne E. Schottinger, Michael H. Kanter, Andrea Smith
Journal: Journal of Clinical Oncology (2013)

177 Background: The Institute of Medicine report "To Err is Human" highlighted two vulnerabilities that introduce possible diagnostic errors — information overload and failure to follow up abnormal cases. The Southern California Permanente Regional Safety Net program was instituted to identify, using electonic medical records, instances where these inadvertent outpatient safety lapses may have occurred and intervene before patient harm develops. A centralized regional team catches the omission and intervenes to ensure necessary follow up care, early diagnosis, treatment monitoring, or preventing harmful interactions from medications. Methods: For colorectal cancer detection and prevention, a safety net system was already in place to ensure the prompt evaluation of a positive fecal occult blood screening test with colonoscopy. However, evaluation of late stages of colorectal cancer at presentation revealed that failure to diagnose/follow up signs of iron deficiency anemia or rectal bleeding (often attributed to hemorrhoids) were opportunities to intervene. The electronic medical record is mined for evidence of iron deficiency anemia in laboratory results or a diagnosis of rectal bleeding that was not followed by a colonoscopy in patients aged 50-75. A list of these patients is reviewed quarterly by a gastroenterologist, who contacts the primary care physician to arrange colonoscopy. Results: During the first six months of the program, 42 patients, aged 52-75, underwent colonoscopy for evaluation of either evidence of iron deficiency anemia or rectal bleeding. Polypectomies were performed in 17 patients (40%) with pathology revealing adenomas in 13 patients and one patient with a bleeding carcinoid tumor. Other findings included hyperplastic polyps, hemorrhoids, diverticular disease, colitis, ulcer, and angiodysplastic lesions. Conclusions: Using an electronic medical record system, an outpatient safety net function allows proactive identification of possible safety issues in the population, helping to avoid late stage diagnoses and adverse outcomes. This system currently encompasses other cancer screening tests, medication monitoring, avoiding harmful medication interactions, and immunizations.
Research on radioimmunotherapy of lung cancer in nude mice using lung cancer monoclonal antibody LC-1 combined with <sup>90</sup>Y
Authors: L. Zeng, D. Ge
Journal: Journal of Clinical Oncology (2004)

9631 Research on Radioimmunotherapy of lung cancer in nude mice using lung cancer monoclonal antibody LC-1 combined with 90Y Abstract Background: to evaluate potential clinical roles of monoclonal antibody (MoAb)-based therapies in the treatment of lung cancer. Methods: Anti-lung cancer monoclonal anibody LC-l IgM was combined with 90Y to produce radioimmunological targeting drug. Human lung cancer tissue was inoculated subcutaneously in 35 nude mice. They were randomized into seven groups while the tumor is 5mm in diameter. The groups were divided by the dose of the drug injected to the tail vein of the mice: blank group,LC-1 IgM, 90Y50uCi, 50uCi, l50uCi, 300uCi and 400uCitherapy groups. The size of the tumor was measured weekly and the mice were killed in four weeks after treatment. The tumors were resected and weighed. Results: As compared to blank group, therapy groups' tumor growth was inhibited and the inhibition was dose and time dependent. The inhibition rates of 300uCi and 400uCi grIoups were significantly different(<0.05). Conclusions: The results indicated that the radioimmunological drug made from lung cancer monoclonal anibody LC-1IgM and 90Y can specifically localise in tumor tissue and ensure radioimmunological targeting therapy, so has underlying clinical value. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration National Natural Science Foundation of China
Adenoid Cystic Carcinoma Can Be Driven by <i>MYB</i> or <i>MYBL1</i> Rearrangements: New Insights into MYB and Tumor Biology
Authors: Thomas J. Gonda, Robert G. Ramsay
Journal: Cancer Discovery (2016)

Abstract Summary: A majority of adenoid cystic carcinomas (AdCC)—rare tumors of the salivary gland and some other organs—have recently been found to be driven by chromosomal translocations resulting in MYB–NFIB fusions. Brayer and colleagues and Mitani and colleagues have now reported that AdCCs can alternatively be driven by similar rearrangements involving a second MYB family gene, MYBL1, and that these two drivers act in remarkably similar ways. Cancer Discov; 6(2); 125–7. ©2016 AACR. See related article by Brayer et al., p. 176.